Translational Medicine in CNS Drug Development, Volume 29, is the first book of its kind to offer a comprehensive overview of the latest developments in translational medicine and biomarker techniques. With extensive coverage on all aspects of biomarkers and personalized medicine, and numerous chapters devoted to the best strategies for developing drugs that target specific disorders, this book presents an essential reference for researchers in neuroscience and pharmacology who need the most up-to-date techniques for the successful development of drugs to treat central nervous system disorders.
Despite increases in the number of individuals suffering from CNS-related disorders, the development and approval of drugs for their treatment have been hampered by inefficiencies in advancing compounds from preclinical discovery to the clinic. However, in the past decades, game-changing strides have been made in our understanding of the pathophysiology of CNS disorders and the relationship of drug exposure in plasma and CNS to pharmacodynamic measures in both animals and humans.
- Includes comprehensive coverage of biomarker tools and the role of personalized medicine in CNS drug development
- Discusses strategies for drug development for a full range of CNS indications, with particular attention to neuropsychiatric and neurocognitive disorders
- Includes chapters written by international experts from industry and academia
Sprache
Verlagsort
Verlagsgruppe
Elsevier Science & Techn.
ISBN-13
978-0-12-803164-3 (9780128031643)
Schweitzer Klassifikation
1. Translating animal models of obesity and diabetes to the clinic2. Biomarker-guided drug development for better defined early patient studies and clinical trial efficiency3. Modeling and simulation in the translational pharmacology of cns drugs4. Functional measurements of central nervous system drug effects in early human drug development5. Experimental medicine approaches in cns drug development6. New approaches in translational medicine for phase i clinical trials of cns drugs7. Translational approaches for antidepressant drug development8. Biomarker opportunities to enrich clinical trial populations for drug development in schizophrenia and depression9. Applications of neuroimaging biomarkers in cns drug development10. Pet occupancy and competition in translational medicine and cns drug development11. Stable isotope labeling kinetics in cns translational medicine: introduction to silk technology12. Applications of neurophysiological biomarkers in cns drug development: focus on psychoses13. Heart rate variability as a translational biomarker for emotional and cognitive deficits14. Drug discovery in psychiatry: time for human genome-guided solutions15. Use of cognition to guide decisions about the safety and efficacy of drugs in early-phase clinical trials16. Digital biomarkers in clinical drug development17. Lessons learned from public private partnerships and consortia: the adni paradigm18. Regulatory perspectives on the use of biomarkers and personalized medicine in cns drug development: the fda viewpoint19. Regulatory considerations for the use of biomarkers and personalized medicine in cns drug development: a european perspective20. Regulatory science objectives and biomarker qualification through public-private partnerships are critical to delivering innovative treatments for cns diseases21. The assessment of cognition in translational medicine: a contrast between the approaches used in alzheimer's disease and major depressive disorder22. Translational medicine strategies in drug development for neurodevelopmental disorders23. Translational medicine strategies in drug development for mood disorders24. Translational medicine strategies in alzheimer's disease drug development25. Experimental medicine models in generalized anxiety disorder and social anxiety disorder26. Translational medicine strategies in ptsd drug development27. Unmet medical needs in the treatment of depression and the clinical development of a differentiated antidepressant: a translational line of evidence28. Translating neurobiology into practice in tobacco, alcohol, drug, and behavioral addictions29. Translational medicine strategies for drug development for impulsive aggression30. Hypothesizing major depression as a subset of reward deficiency syndrome (rds) linked to polymorphic reward genes: considerations for translational medicine approaches for future drug development31. Traveling through the storm: leveraging virtual patient monitoring and artificial intelligence to observe, predict, and affect patient behavior in cns drug development
